Research programme: mesenchymal stem cell-derived secretory factors - Sentien Biotechnologies

Drug Profile

Research programme: mesenchymal stem cell-derived secretory factors - Sentien Biotechnologies

Alternative Names: Extracorporeal stem cell therapy - Sentien Biotechnologies; MSC-derived secretions; Sentinel; Stem cell therapeutics device - Sentien Biotechnologies

Latest Information Update: 02 Feb 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sentien Biotechnologies
  • Class Stem cell factors
  • Mechanism of Action Immunosuppressants; Stem cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Acute kidney injury; Liver disorders; Myocardial infarction
  • Research Autoimmune disorders; Renal failure
  • No development reported Adult respiratory distress syndrome; Graft-versus-host disease; Pancreatitis

Most Recent Events

  • 01 Jan 2017 Early research in Autoimmune disorders and Renal failure in USA (Parenteral) (Sentien Biotechnologies website)
  • 01 Jan 2017 Preclinical trials in Liver disorders and Myocardial infartion in USA (Parenteral) (Sentien Biotechnologies website)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Acute kidney injury in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top